Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids
The publication in the Proceedings of the National Academy of Sciences of the US (PNAS) by scientists at the Emory University (Atlanta), the Binghamton University-State University of New York (New York) and ReveraGen Biopharma Inc.  summarizes structural, biophysical, computational and biochemical data that further explain the unique pharmacological properties of vamorolone, clearly setting it apart from standard corticosteroids, including those currently used as treatment for patients with DMD. It extends previous publications which characterized the unique pharmacological properties of vamorolone, a dissociative steroidal drug candidate that decreased muscle inflammation and improved muscle strength in mouse models of DMD [2-4]. Moreover, initial open-label clinical trials with vamorolone showed dose-responsive efficacy in DMD while biomarker measurements indicated reduced safety concerns typically associated with traditional corticosteroid treatments [5-7].
Vamorolone and the active metabolites of prednisone and deflazacort were compared regarding their molecular interactions with the target receptor (glucocorticoid receptor, GR), and required accessory proteins (co-activators, co-repressors). Vamorolone has one less single contact point with the GR compared to prednisone and deflazacort, and this changes conformation of the accessory protein binding sites. The data further show that vamorolone uniformly weakens co-activator associations, which leads to loss of gene transcriptional activities associated with safety concerns of corticosteroids. In contrast, vamorolone retains co-repressor binding necessary for anti-inflammatory activities associated with efficacy of corticosteroids. This suggests that vamorolone is a first-in-class partial agonist of the GR, and explains the dissociative and advantageous pharmacological properties seen in mouse models of inflammatory disease, and DMD patients.
“Our study provides a molecular model for understanding of the unique mode of action of vamorolone, which distinguishes it from standard glucocorticoids such as prednisone and deflazacort”, said Eric A. Ortlund, PhD, Professor at Emory University and corresponding author of the publication.
“We now understand the molecular basis of the dissociative properties of vamorolone, which retains the anti-inflammatory capacity but result in a reduced liability for undesirable side effects. Vamorolone is in advanced clinical development with the potential to offer an alternative to current standard of care treatments in young boys with DMD,” said Eric Hoffman, PhD Vice President of Research at ReveraGen BioPharma and co-author of the study.
About ReveraGen BioPharma
Puldysa® and Raxone® are trademarks of Santhera Pharmaceuticals.
For further information please contact:
Disclaimer / Forward-looking statements
# # #
Privacy for IoT
Get Your Factories Connected -- Fast!